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A BSTRA CT
Introduction: Treatment of co-morbidities, including bronchial asthma (BA) and coronary heart disease (CHO), is a relevant issue of modern therapy.
The aim of the research is to study the impact of long-term intake of pioglitazone on the development of inflammation and E0 in patients with BA concurrent with CHD. 
Material and methods: The clinical study involved 50 people aged 40-75 who suffered from asthma concurrent w ith CHO. On the first day of the study, blood samples were 
collected and clinical examinations were performed, after which patients were randomized and divided into the control group who continued to receive only the standard therapy, 
and the study group, who received pioglitazone (Pioglar, Ranbaxy, India) 15 mg once a day along with comprehensive therapy. Re-examination was carried out in 6 months. 
Results: It has been found that inclusion, of pioglitazone in the course of standard therapy in patients with asthma concurrent with coronary heart within 6 months is a more efficient 
scheme than the course of standard therapies. According to the data obtained from the patients, there was a significant decrease in respiratory rate (p<0.01), levels of systolic blood 
pressure (p<0.001) and diastolic blood pressure (p<0.001). Administering pioglitazone contributed to the improvement of respiratory function and airflow obstruction, increased 
FEV1 performance (p<0.01) and Tiffeneau index (p<0.05). In patients of the study group, intake of pioglitazone helped to reduce angina. Intake of pioglitazone showed a significant 
decrease in the frequency of angina pectoris FCII (p<0.05) and a significant increase in the frequency of angina FCI (p<0.05), increase in the rate of threshold load power (p<0.05). 
In assessing endothelium-dependent vasodilation of the brachial artery, it has been noted that intake of pioglitazone by patients with asthma concurrent with coronary heart disease 
resulted in a statistically significant increase in the diameter of the brachial artery by an average of 4% (p<0.0001), the maximum blood flowvelocity (TAMX) by an average of 40 % 
(p<0.0001), A% diameter increase in the brachial artery (p<0.0001), and achieved positive indicators of Rl (p<0.0001). In assessing endothelium-dependent vasodilation of brachial 
artery in patients treated with pioglitazone, there was a significant increase in the diameter of brachial artery on average by 5% (p<0.0001) after taking nitroglycerin, an increase in 
A96 diameter ofbrachial artery (p<0.0001) and Rl(p<0.0001). Inclusion of pioglitazone in the complex therapy for 6 months resulted in a significant decrease in the index of systemic 
inflammation hs-CRP (p<0.0001) and adhesion marker sVCArVI-1 (p<0.0001), total cholesterol (p<0.001), triglycerides (p<0.001).
Conclusion: Thus, these data demonstrate the anti-inflammatory and endothelium protective effects of pioglitazone against the background of standard therapy in patients 
with BA concurrent with CHD within 6 months, which may enhance the clinical efficacy in the treatment of these diseases.
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IN T R O D U C T IO N
Treatment of co-morbidities, including bronchial asthma 
(BA) and coronary heart disease (CHD), is a relevant issue 
of modern therapy. The high risk of cardiovascular events 
is directly related to the development of inflammation and 
endothelial dysfunction (ED), which are crucial in the damage 
of bronchopulmonary and cardiovascular systems [1].
In recent years, the idea of he correction of systemic 
inflamm ation and ED has acquired a leading role in
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the pathogenetic treatment of asthma concurrent with 
CHD [2], since the airway inflammation triggers the 
development of systemic inflammation and ED [3].
However, inhaled corticosteroids (ICS), which are used in 
the basic anti-inflammatory therapy, are not always clinically 
effective and pathogenetically feasible in BA against the 
background of CHD [4]. Earlier in the works of several authors 
[5,6,7] it has been demonstrated that thiazolidinediones have 
better clinical effects than inhaled corticosteroids in asthma
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It has been noted that thiazolidinediones reduce asthma 
exacerbation by 21 % in patients with asthma and type 2 diabetes 
mellitus (DM), as compared with patients taking inhaled 
corticosteroids [6]. Therefore, special attention was drawn to 
medications of thiazolidinedione group, namely pioglitazone.
Pioglitazone is an agonist of nuclear peroxisome 
proliferator-activated receptor-gamma (PPARy), providing 
pleiotropic effects, in particular antihyperglycemic, 
hypolipidemic, immunomodulating and anti-adhesion 
actions [7]. The data on the participation of thiazolidinediones 
in the regulation of inflammation and airway remodeling in 
asthma are being accumulated [8.9.10]. PERISCOPE study 
results have shown that pioglitazone prevents the progression 
of coronary atherosclerosis in patients with CHD against the 
background of type 2 diabetes [11]. However, there is still an 
open question as to the tactics of prescribing the medications 
of the group: duration, effectiveness and advantages of this 
therapy in patients with BA concurrent with CHD.
THE AIM
The aim of the research is to study the impact of long-term 
intake of pioglitazone on the development of inflammation 
and ED in patients with BA concurrent with CHD.
MATERIAL AND METHODS
The clinical study involved 50 people aged 40-75 who 
suffered from asthma concurrent with CHD. The study 
was conducted in the period from 2011 to 2013 on the 
basis of Poltava City Hospital No.l and Research Institute 
for Genetic and Immunological Grounds of Pathology and 
Pharmacogenetics. The study protocol was approved by the 
Bioethics Committee of Ukrainian Medical Stomatological 
Academy. Before the start of the study, informed consent 
was obtained from all the participants.
Inclusion criteria were as follows: asthma of varying 
severity in remission, stable exertional angina.
Exclusion criteria were the history of chronic obstructive 
pulmonary disease (COPD), myocardial infarction (MI), 
clinically significant cardiac rhythm and conduction 
disturbances, interventions, malignant arterial hypertension 
(AH), chronic heart failure (HF) of III-IV functional class 
(FC), acute cerebrovascular accident in the acute and 
subacute periods, diabetes mellitus (DM), glomerular 
flitration rate<60 ml / min, increased transaminase levels by 
3 or more times, edema of any etiology systemic connective 
tissue diseases, cancer and hematological diseases, severe 
infectious diseases, the presence of hypersensitivity to 
pioglitazone, inability to perform the spirometry protocol.
The diagnosis of asthma was confirmed on the basis of 
the criteria of Global Strategy for asthma management 
and prevention (GINA, revision as of 2009-2014) [12]. 
CHD was diagnosed in patients by the presence of 
angina of FC I-IV according to the classification of the 
Canadian Association of Cardiology and circulatory failure 
phenomena according to the classification of the New York 
Heart-Association (NYHA).
At the screening stage, patients were examined to verify the 
diagnoses of asthma and coronary heart disease; to medical 
history and allergy data were collected, anthropometric 
measurements -  weight, height, body mass index (BMI) 
(kg/m2) were determined. Respiratory function (RF) 
was assessed by spirometry (spirograph “Kardioplyus”, 
Ukraine) with broncho dilator test (salbutamol) by ATS 
and ERS criteria. Further, the electrocardiogram (ECG) 
data, and blood pressure (BP) -  systolic (SBP) and diastolic 
(DBP) param eters were recorded. Bicycle ergometry 
was conducted on the bicycle ergometer Veloergotest 05 
(Ukraine) by the method of stepwise load increase with the 
consequent extension in capacity under the supervision of 
electrocardiogram (ECG) and blood pressure. Power at the 
stage I was 150 kgm/min (25 W), at II -  300 kgm/min (50 
W), at III -  450 kgm/min (75 W), at IV -  600 kgm/min 
(100 W), at V -  750 kgm/min (125 W), at VI -  900 kgm/ 
min (150 W), the length of each stage was 3 min. Tolerance 
of CHD patients to exercise capacity was calculated 
according to the value of the threshold load capacity and 
volume of work performed. The threshold load capacity of 
150 kg/min (25 W) was considered very low and consistent 
with angina of FC IV; 300 kgm/min (50 W) -  low, FC III; 
450 -  600 kgm/min (75-100 W) -  medium, FC II; 750 
kgm/min (125 W) and above -  high exercise capacity, FC 
I. The criteria for termination of bicycle ergometry were 
conventional clinical or ECG signs of myocardial ischemia.
All patients to be included in the clinical trial were prescribed 
conventional treatment, and after the screening study -  
standard medical therapy, including inhaled corticosteroids 
(ICS) in the low, medium or high doses, depending on asthma 
severity in combination with inhaled long-acting (32-agonists 
(ILABA.), amlodipine 5 mg once a day, atorvastatin 10 mg once 
a day, 7 5 acetyisalicylic acid mg once a day, isosorbide dinitrate 
20 mg 2 times a day. Some patients received an additional 
number of the following medications as prescribed for more 
than 1 month before the inclusion: anti-leukotrienes -  2 
persons (rnontelukast 10 mg once a day), 28 people depending 
on the blood pressure dynamics were taking angiotensin­
converting enzyme inhibitors (ACE, enaiapril 5 mg once 
a day). Patients were receiving the prescribed treatment 
during the month to achieve stable indicators for inclusion in 
the study. On the first day of the study, blood samples were 
collected and clinical examinations were performed, after 
which patients were randomized and divided into the control 
group who continued to receive only the standard therapy, and 
the study group, who received pioglitazone (Pioglar, Ranbaxy, 
India) 15 mg once a day along with comprehensive therapy. 
Re-examination was carried out in 6 months.
Assessment of endothelial function was performed 
using the m ethod suggested by D.S. Ceiermajer et al. 
(1994) [13] on the ultrasound scanner Ultima PA expert 
(Rodman, Ukraine) in triplex mode with linear transducer 
of operating frequency of 05.12 MHz. Initially, the diameter 
of the brachial artery and the maximum linear blood flow 
velocity (TAMX) were measured.
The functional status of endothelium wTas evaluated using 
samples of postocclusive reactive hyperemia, where the
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diameter o f the brachial artery and the maximum linear 
blood flow velocity were determined initially and at the 60th 
second after 5 minutes o f the brachial artery compression by 
the pressure o f  50 mm Hg above the systolic blood pressure 
(SBP) level in  the patient. Further, endothelium-dependent 
vasodilation (EDVD) was calculated -  the degree o f  increase 
in  the brachial artery diameter (A% index) and reactivity 
index (RI) -  the ratio o f TAMX after the test to that of  
before the trial. To assess the myogenic mechanism for the 
regulation o f vascular tone, the test with nitroglycerin was 
used, which was determined by the diameter o f  the brachial 
artery and TAMX after the test and 2 minutes after the 
intake o f  0.5 mg sublingual nitroglycerin (NG). Afterwards, 
endothelium vasodilation was calculated as the degree of 
growth of the brachial artery diameter and RI (the ratio of 
TAMX before the test to that o f after the test).
In the test o f  postocclusive reactive hyperem ia, the 
dilatation o f brachial artery, indicating the preservation of 
local mechanisms o f vascular tone regulation, on the average 
is about 10% of the original diameter, while in  the intake of 
NG -  about 15%. The value o f RI over 1.1 was regarded as 
a positive reaction o f the blood flow, which indicates the 
preservation o f endothelium function. The negative (the 
value o f RI from 0.9 to 1.1) and paradoxical (the value o f RI 
less than 0.9) types o f  reactions are considered abnormal and 
indicate ED. To eliminate the effect o f nitrates on the results 
of diagnostic tests (tests with RH and NG), the medication 
was withdrawn one day prior to the event.
The level o f systemic inflammation and active adhesion 
molecules was studied by determining the high-sensitivity
C-reactive protein (hs-CRP), soluble forms o f adhesion 
molecules o f intravascular cell-1 (VC AM -1) and intercellular 
adhesion m olecu les-1 (IC A M -1) in  accordance w ith  
manufacturers protocols («DRG», «BioScience», USA).
Complete blood count, urinalysis, and biochemical analysis 
o f blood (glucose, bilirubin, ALT, AST, total protein, urea, 
creatinine, residual nitrogen, triglycerides, total cholesterol, 
thymol) were conducted by conventional methods.
Statistical processing of the data was performed using the 
program «STATISTICA 6.0» (StatSoftlnc., USA). Descriptive 
statistics of the research results is presented for qualitative 
characteristics in the form of frequencies, percentages, for 
quantitative -  in the form of arithmetic mean values and standard 
errors. Significant differences between the indices were calculated 
for qualitative characteristics (frequencies) using Fishers exact test 
and x2, for quantitative -  Students t-test. For all types of analysis, 
the statistically significant differences at p<0.05 were considered.
RESULTS
The results showed that both groups of patients initially had 
significant differences in only a few parameters (Table I). 
Patients of the control group in contrast to the study group 
showedincreasedfrequencyin the indicators ofHF of 1 degree 
(1 6  and 10 patients, respectively; p<0.05) and in the study 
group there were more patients with HF of 0 degrees (15 and 
7 patients, respectively; p<0.01). Groups differed significantly 
from each other in terms of asthma duration (p<0.02), as well as 
by the frequency of respiratory distress of 2 degree (15 patients 
in the control group and 9 in the study group, p<0.05).
Table I. Clinical characteristics of examined patients w ith asthma against the background of coronary heart disease at the randomization stage
Parameter
Control group 
(n =25)
Value, abs. (%)
Study group 
(n =251
Value, abs. (%)
Reliability .
.
G e n d e r: Women Men 7 (18) /2 8  (72) 10 (4 0 )/1 5  (60) >0.05 />0 .05
A g  e , years 56.64±1.69 54.52+1.73 >0.05
H e ig h t, cm 166.4±1.73 167.2±1.44 >0.05
D u ra tio n  o f  th e  course:
BA 16.4±2,15 9.72+1.6 < 0 .0 2
CHD 5.88±0.66 4.32±0.5 >0.05
BA concurrent with CHD 5.24±0.55 3.92±0.5 >0.05
S e v e r ity  d e g re e  o f  BA:
In term ittent 2(8) 3(12) >0.05
p ers is ten t:
m ild 5(20) 7(28) >0.05
m edium  severity 6(24) 6(24) >0.5
severe 12 (48) 9(36) >0.05
R e s p ira to ry  fa ilu re :
0 degree 8(32) 10(40) >0.05
1 degree 2(8) 6(24) >0.05
2 degree 15(60) 9 (36) < 0 .0 5
H e a r t  fa ilu re :
0  degree 7(28) 15(60) < 0 .01
1 degree 16(64) 10(40) < 0 .0 5
2 degree 2(8) 0 >0.05
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Table II. Changes of clinical parameters in patients with bronchial asthma concurrent w ith  
coronary heart disease during the long-term treatment w ith pioglitazone ___________
Control group (n~25) ________  Study group (n~25)
Parameter Before After Reliability Before After Reliability Reliability
treatment treatment (P,) treatment treatment (Pj)
Weight, kg 83.20±3.68 82.813.68 >0.05 84.8813.64 84.6813.69 >0.5 p3> 0.05. p4> 0.05
Bronchodilator test, % 20.1612.18 20.521207 >0.05 17.2612.03 16.4411.65 >0.5 p3> 0.05. p4> 0.05
Bronchodilator test, ml 357.2140.55 362.32139.16 >0.05 347.4137.71 3423413131 >0.5 p3 > 0.05. p4> 0.05
Systolic blood pressure, 
mm Hg 134.0012.91 132.201130 >0.05 132.0011.47 125.601131 <0.001 p3> 0.05. p4< 0.001
Diastolic blood pressure, 
mm Hg 85.4011.74 83.810.86 >0.05 84.2010.83 79.210.67 <0.001 p3> 0.05. p4< 0.001
Cardiac rate 71.5212.16 69.80+1.89 >0.05 72.8412.32 70.8012.48 >0.05 p ,>  0.05. p4> 0.05
Stress, W 100.0014.9 109.0014.21 >0.05 107.0014.8 120.0012.45 <0.05 p3> 0.05. p4 < 0.05
Bicycle Angina: FC
ergometry 1 cl° 5S 
II class
8(32) 13(52) >0.05 16(64) 21(84) <0.05 p3 < 0 .05. p4< 0.01
13(52) 10(40) >0.05 9(36) 4(16) <0.05 p3> 0.05. p4< 0.05
III class 4(16) 2(8) >0.05 0 0 - p3<0.05. p4> 0.05
Note: here and in Tables 3 ,4 ,5 :  p i -  comparison before and after treatment in the control group, p i  -  comparison before and after treatment in the study 
group, p3  - comparison before treatment in the control group to study group, p4 -  comparison after treatment in the control group to study group.
Initially (Table II), the predominance o f  indicators o f  
stable angina o f FC I was revealed (16 and 8 patients, 
respectively; p<0.05) in the study group in contrast to the 
control group, whereas in the control group there were 
more patients with stable angina o f FC III (4 and 0 patients, 
respectively; p<0.05).
After randomization, the study group began receiving 
pioglitazone against the background o f standard therapy 
tor 6 months, and the control group continued to receive 
standard therapy.
It has been found that inclusion of pioglitazone in the course 
of standard therapy in patients with asthma concurrent 
with coronary heart within 6 months is a more efficient 
scheme than the course o f  standard therapies (Table II). 
Thus, according to the data obtained from the patients, 
there was a significant decrease in respiratory rate (p<0.01), 
levels o f  systolic blood pressure (pcO.OOl) and diastolic 
blood pressure (pcO.OOl). Adm inistering pioglitazone  
contributed to the improvement o f  respiratory function 
and airflow obstruction, increased FEV[ performance 
(p<0.01) and Tiffeneau index (p<0.05) (Fig. 1). In patients 
o f the study group, intake o f  pioglitazone helped to reduce 
angina. According to bicycle ergometry data, in patients with 
asthma concurrent with coronary heart disease, intake of 
pioglitazone showed a significant decrease in the frequency 
of angina pectoris FC II (p<0.05) and a significant increase 
in the frequency of angina FC I (p<0.05), increase in the rate 
of threshold load power (p<0.05).
Intake o f the standard complex o f medical therapy by 
patients with asthma concurrent with CHD also had a 
positive, but less pronounced effect. Significant decline in 
respiratory rate (pcO.Ol), increased rates o f FEVj (p<0.05) 
and Tiffeneau index (p<0.05) (Fig. 1) have been registered 
in patients o f the control group.
A statistically significant difference in the dynam ics 
for the period o f 6 months between the groups has been  
detected: patients with asthma concurrent with CHD in 
the study group had greater decrease in SBP (pcO.OOl) 
and DBP (pcO.OOl), reduction in the frequency o f angina 
pectoris FC II (pc0.05) and increased frequency o f angina 
pectoris FC I (pcO.Ol), increase in the rate o f  threshold 
load power (pc0.05) as compared with the control group.
The analysis o f the data showed a significant improvement in 
the functional activity o f endothelium and blood flowvelocity in 
patients with asthma against the background of coronary heart 
disease receiving standard therapy with pioglitazone as compared 
to patients receiving only standard treatment (Table III). 
In assessing endothelium-dependent vasodilation o f the 
brachial artery, it has been noted that intake o f pioglitazone by 
patients with asthma concurrent with coronary heart disease 
resulted in a statistically significant increase in the diameter 
o f the brachial artery by an average o f  4% (pcO.OOOl), the 
maximum blood flow velocity (TAMX) by an average o f  40 
% (pcO.OOOl), A% diameter increase in the brachial artery 
(pcO.OOOl), and achieved positive indicators o f RI (pcO.OOOl), 
while the intake o f  standard therapy resulted in a slight 
increase of TAMX on average by only 10% (pc0.05) and 
increase in the A% diameter of the brachial artery (pc0.05), 
increase o f RI (pc0.05). In assessing endothelium-dependent 
vasodilation o f brachial artery in patients treated with 
pioglitazone, there was a significant increase in the diameter 
o f brachial artery on average by 5% (pcO.OOOl) after taking 
nitroglycerin, an increase in A% diameter o f brachial artery 
(pcO.OOOl) and RI (pcO.OOOl), whereas in patients receiving 
standard therapy there was a slight increase in A% diameter 
of the brachial artery (pcO.05) and RI (pc0.05). It has been 
noted that in the dynamics of the 6 months therapy in the 
study group as compared with the control group there were
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Fig.1. Changes in the external respiration in patients with  
bronchial asthma concurrent w ith coronary heart disease 
during the long-term treatment with pioglitazone
significantly increased parameters of endothelium-dependent 
vasodilatation (diameter o f the brachial artery after RH test 
(p<0.05), TAMX after RH test (p<0.05), RI (p<0.05) and 
A% diameter of the brachial artery (p<0.05)), endothelium- 
independent vasodilatation (diameter of the brachial artery 
after the test with NG (p<0.05), IR (p<0.05), A% diameter of 
the brachial artery (p<0.05)).
At the next stage o f  the research, the markers o f  acute 
inflammation and adhesion in the groups o f  patients were 
studied (Table IV). Inclusion o f pioglitazone in the complex 
therapy for 6 months resulted in a significant decrease in 
the index o f systemic inflammation hs-CRP (p<0.0001) 
and adhesion marker sVCAM-1 (p<0.0001). A similar 
significant decrease in the same indicators was identified 
in  the control group after the standard therapy. A more 
pronounced decline by 1.94 times in the sVCAM-1 index 
was observed in the dynamics o f  6 months in patients o f  
the study group than in the control group (p<0.0001).
Tables V  and VI show the changes in general clinical 
and biochemical blood parameters in groups o f examined 
patients. According to the data presented in tables, inclusion of 
pioglitazone in the treatment complex for 6 months resulted in 
a significant reduction in the number o f leukocytes (p<0.01), 
erythrocyte sedimentation rate (p<0.05), total cholesterol 
(pcO.OOl), triglycerides (pcO.OOl), reduced thym ol test 
(p<0.02). In the control group after the standard therapy, 
there was stabilization o f parameters, except for the significant 
increase in the concentration of glucose (p<0.05). In general, 
the groups did not significantly differ in  terms o f parameters 
after 6 months o f treatment, except for significant reduction 
of ESR (p<0.05) and total cholesterol (pcO.OOOl) in the study 
group as compared with the control group.
CONCLUSIONS
Currently, the most effective medications in the treatment 
o f  asthma are inhaled corticosteroids, which reduce the 
frequency and severity o f symptoms, exacerbations o f the 
disease, improve exercise tolerance, and patient’s quality 
o f  life. However, despite the apparent benefits, the therapy 
with inhaled corticosteroids has a number o f drawbacks 
and limitations: intake o f  medications prevents correction of 
progressive decrease in the functional activity o f the lungs and 
aggravation o f atherosclerosis, as well as the need for life-long 
intake [4]. Therefore, especially important is the problem of 
finding a new alternative medication for the treatment o f  
asthma against the background o f coronary heart disease.
However, despite this fact [14], there are certain concerns 
about the use o f medications in asthma due to the necessity 
o f long-term intake and the use o f  high doses, since they 
can cause a number o f undesirable side effects, such as 
suppression o f cortisol synthesis, decreased bone density, 
oral candidiasis [4]. In addition, a small proportion o f  
patients are resistant to anti-inflam m atory effects o f  
steroids. Consequently, there is a need for new  anti­
inflammatory medications to treat these diseases.
Our data showed that the inclusion o f pioglitazone in 
the treatment complex o f  patients with asthma concurrent 
with coronary heart disease for 6 m onths was a more 
clinically effective schem e as compared with standard 
therapy. Favorable clinical effect o f  pioglitazone is due to 
improved respiratory function and airflow obstruction, 
decreased angina pectoris FC in patients with asthma 
against the background o f coronary heart disease. It should 
be noted that in one o f our earlier studies, the intake of 
pioglitazone for 3 months along with a standard course of 
therapy in patients with asthma against the background 
o f coronary heart disease also led to the reduction o f  
bronchial ob stru ction , system ic in flam m ation , and  
improved performance o f EDVD and EIDVD [15]. To 
date, the effect o f  pioglitazone on the bronchopulmonary 
system is not completely studied. However, our findings 
are consistent with data from other experimental studies 
that show that taking pioglitazone in patients with BA 
reduces bronchial obstruction and inflammation in the 
lung tissues by suppressing the growth o f  sm ooth muscle
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Table I I I .  Changes in the functional activity of endothelium in patients w ith bronchial asthma concurrent 
with coronary heart disease during the long-term treatment with pioglitazone
Control group (n=25) Study group (n=25)
Parameter
'  ’ « 4 '-  <?,*
Before
treatment
After
treatments
Reliability
(P,)
Before
treatment
After
treatment
Reliability
(P7) .
Reliability ,
Diameter of the brachial 
artery before the test, cm 4.23±0.07 4 .19+ 0 .04 >0.05 4.23± 0.05 4.23± 0.05 >0.05 1 V
 
V
 
o 
o 
! o
 o
Ln
Diameter of the brachial 
artery after the test, cm 4.35±0.07 4.4±0.05 >0.05 4.37± 0.06 4.58± 0.06 <0.0001 P
P
A
 
V
 
O
 O
 
o
 o
 
! u
i m
Endothelium-
dependent
TAMX before the test, 
cm/s 6 .32+0.4 6.7±0.35 >0 .05 5.96±0.28 6.94± 0.25 >0 .05
p 3 > 0.05  
P4>  0.05
vasodilatation 
(test with RH) TAMX after the test, cm/s 6.01 ±0.38 6.65± 0.36 <0.05 5.77±0.30 8.10±0.27 <0.0001
p3 > 0.05  
P4<0.05
Rl 0.95±0.01 1.00±0.02 <0.05 0.96±0.01 1.17±0.02 <0.0001 p3 >  0.05  P4 <  0.05
A% diameter of the 
brachial artery
3.08±0.21 5.01 + 0 .32 <0.05 3.51±0.15 8.47±0.16 <0.0001 p3 < 0.05  P4< 0.05
Diameter of the brachial 
artery before the test, cm 4.25±0.07 4.21 ± 0.04 >0 .05 4.24±0.05 4.24± 0.05 >0.05
p 3 > 0.05  
P4> 0.05
Diameter of the brachial 
artery after the test, cm 4.66+0.08 4.64±0.05 >0.05 4 .65+ 0 .06 4.87± 0.07 <0.0001
p3 > 0.05  
p 4 < 0 .0 5
Endothelium-
independent
vasodilatation
TAMX before the test, 
cm/s 5.95±0.39 6.67± 0.34 <0.01 5.91+0 .32 6.98±0.25 <0.0001
p3 > 0.05  
P4 > 0.05
TAMX after the test, cm/s 6,23±0.43 6.68±0.35 >0.05 6 .24+ 0 .36 5.95±0.25 >0.05 p 3 >  0.05  
P4 >0.05
(test with NG)
Rl 0.96±0.01 1.00±0.02 <0.05 0.95±0.01 1.18±0.02 <0.0001 p3 > 0.05  P4< 0.05
A% diameter of the 
brachial artery 9.86±0.21 10.34+0.31 < 0 .0 5 9.59+0.27 14.92±0.18 <0.0001
p3 > 0.05  
P4 < 0.05
cells of the respiratory tract [5], reducing the synthesis 
and production of pro-inflammatory cytokines in the 
bronchoalveolar lavage [16]. The study by Narala V.R. 
et al. (2007) has found higher anti-inflammatory and 
remodeling bronchi effectiveness of pioglitazone as 
compared to dexamethasone [17].
Bronchial inflammation provokes the development of 
systemic inflammation, which, along with developing 
hypoxia, activates platelets, and developing oxidative stress 
-  LDL oxidation with the formation of foam ceils, which 
triggers changes in atherosclerotic endothelium. High levels 
of proinflammatory cytokines (IL-3, IL-4, IL-5, IL-6, IL-1 and 
TNF-a), neurotransmitters and proteins of the acute phase 
of inflammation (CRP) is a key marker in the formation of 
systemic inflammation and atherosclerosis [18].
Our study showed that the long term administration 
of pioglitazone for 6 m onths helped to reduce the 
inflammatory processes by inhibiting C-reactive protein, 
ESR, and sVCAM-1 adhesion molecule in the blood of 
patients with asthma concurrent with CHD. Our findings 
are consistent with other studies which have shown that 
activation of PPARy receptors by pioglitazone in the cells 
of lung tissue causes reduction of allergic inflammation, the 
amount of eosinophils and mast cells, increased production
of anti-inflam m atory cytokine IL-10 (antagonist of 
proinflammatory cytokines Tx2 lymphocytes (IL-4 and IL- 
5) and IgE synthesis inhibitor), decrease in the synthesis of 
IL-4 and IL-5 in the smooth muscle cells and monocytes, 
the medication inhibits the expression of TNF-a, IL-6 and 
IL-1 [19]. The molecular mechanism by which pioglitazone 
regulates the inflammatory response is associated with 
the suppressed expression of the pro inflam m atory  
transcription gene, in particular members of the families 
of nuclear factor NF-kB, AP-1, STAT-1 and NFAT [20].
Endothelial dysfunction has an important role in the 
development of thrombosis, neoangiogenesis, vascular 
remodeling, intravascular activation of platelets and 
white blood cells. Predominant endothelial dysfunction 
depends on the development of immune-inflammatory 
processes. Activated endothelium  with high level of 
expression of ICAM-1, VCAM-1 adhesion molecules is 
one of the earliest manifestations of atherosclerosis, which 
indicates the possibility of monocytes and T-lymphocytes 
to attack endothelium and penetrate the intima and induce 
exacerbation of inflammation and destruction processes [3].
In our study, it has been shown that the long-term  
use of pioglitazone for 6 months had a positive impact 
on improving the functional activity of endothelium
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Table IV.The activity of inflammatory markers in patients with bronchial asthma concurrent with  
coronary heart disease during the long-term treatment with pioglitazone
Control: g roup (n=,25) S tudy group (n = 25 )
Param eter Before
tre a tm e n t
A fter
trea tm en t Reliability { p .)
Before
trea tm en t
A fter
tre a tm e n t Reliability; (p j)
Reliability
hsCRP, m g /l 8.92±1.21 1.3510.31 < 0 .0001 10.07+1.25 0.9810.31 < 0.0001 p3 >  0 .05. p4 > 0 .0 5
slCAM-1 418.59±25.37 423.64+39.60 >0 .05 319.14+23.01 384.77127.92 >0 .05 p3 > 0.05. p4 > 0 .0 5
sVCAM-1 3273.641133.68 2132.17169.77 < 0.0001 1488.18+74.50 1098.69160.26 < 0.0001 p3 < 0 .0 0 0 1 , p4< 0 .0 0 0 1
Table V. Changes in blood count of patients with bronchial asthma concurrent with coronary 
heart disease during the long-term treatment with pioglitazone
Control group (n==25);' T C ; ' S tudy g roup  (n=25)
•■C'T B eforetyty  
; trea tm en t
y ty flA fte r  v. 
a ('.treatm ent
. [R eliab ility  , "■BefofbCS;
tre a tm e n t tre a tm e n t
R eliab ility) 
. (P ,)
Reliability
E ry th ro cy tes , x 1 0 ,2/ l 4 .1 5+ 0 .08 4 .2210.08 >0.05 4 .2 2 1 0 .0 6 4 .23+ 0 .05 >0.05 p3> 0.05, p4 > 0 .0 5
H e m o g lo b in , g / l 129 .6+ 2 .69 131.48+2.19 >0.05 133.3212.21 131 .16+ 2 .77 >0.05 p3> 0.05, p4 > 0 .0 5
C o lo r in d e x 0.92+0.01 0.9310.01 >0.05 0.9410.01 0.94+0.01 >0.05 p3< 0 .0 5 , p4 > 0.05
Leukocytes , /  109/ l 6 .2510 .30 6.34+0 ,34 >0.05 6.53+0 .35 5 .55+ 0 .26 <0 .01 p3> 0.05, p4 > 0.05
ESR, m m /h r 13 .12+ 1 .74 14.04+2.00 >0.05 12 .1211 .50 8 .56+ 1 .15 < 0 .0 5 p3 > 0.05, p4 
< 0 .0 5
E osinop hils , % 2 .0810 .33 2 .4410.46 >0.05 2.210 .37 2 .1 6 1 0 .3 4 >0.05 p3 >  0 .05, p4 > 0 .0 5
B asophils , % 0 .2410 .13 0.210.1 >0.05 0.2410.1 0 .2 4 1 0 .0 9 >0 .05 p3> 0.05, p4 > 0 .0 5
S tab , % 2 .9 6+ 0 .44 3.12+0.31 >0.05 3 .3610 .42 2 .6+0.17 >0.05 p3> 0.05, p4 
> 0 .0 5
S e g m e n to n u c ie a r, % 5 7 .7611 .9 61 .1611 .76 >0.05 57 .0 4 1 1 .7 8 57.8411.91 >0 .05 p3> 0 .05 , p4 > 0 .0 5
Lym p h o cy tes , % 2 9 .2811 .58 27.5611.63 >0.05 31 .3 2 1 1 .5 8 2 9 .6811 .62 >0.05 p3 > 0 .05, p4 
> 0 .0 5
M o n o c y te s , % 7.0410 .5 6 .2810 .29 >0.05 6 .00+ 0 .46 7 .0810 .53 >0.05 p3 > 0 .05, p4 
> 0 .0 5
and blood flow velocity, which can help to prevent the 
development of ED in patients with asthma concurrent 
with coronary heart disease. It has also been noted 
that the long-term use of pioglitazone contributed the 
antiadhesive impact by reducing the concentration of the 
sVCAM-1 molecule in the blood, and improved blood 
lipid profile by reducing total cholesterol and triglyceride 
levels in patients with asthma against the background of 
CHD, which in general can also significantly reduce the 
risk of atherosclerosis.
The analysis of m o d ern  ex p e rim en ta l s tud ies 
conclusively proves that the effect of pioglitazone on the 
functional state of cells involved in the atherosclerotic
process in macrophages by inhibiting the production 
of inducible NO-synthase, matrix metalloproteinase-9, 
and in endothelial cells -  IFN-v-induced protein-10, 
m onokine and endothelin-1, in the IFN -y-induced 
T-cells -  chem oattractant-a, and in T-lymphocytes 
-  IL-2 [20, 21]. In a random ized clinical trial, the 
ability of pioglitazone to suppress the thickening of the 
intima-media in the carotid arteries has been pointed 
out [22]. In a multicenter study PROactive (Prospective 
Pioglitazone Clinical Trial In Macrovascular Events), 
which included 5238 patients with type 2 diabetes and 
m acrovascular com plications, the cardioprotective 
role of pioglitazone has been proven, which exceeded
718
ANTI-iNFLAMMATORY AND ENDOTHELIUM PROTECTIVE EFFECT OF LONG-TERM PIOGLITAZONE INTAKE
Table V I. Changes o f biochemical parameters o f blood in patients w ith  bronchial asthma concurrent 
w ith  coronary heart disease during th e  long -te rm  trea tm en t w ith  pioglitazone
- - » Control g roup  (n—25) Study group (n==25)../ +  : f ( 4 «
Param eter Before . 
trea tm en t
A fter Reliability (p.) 
tre a tm e n t ^
Before
tre a tm e n t'
*  A fter  
trea tm en t Reliability (p2)
Reliability
B lood g lucose,
mmol/l 4.45± 0.13 4 .74± 0 .12 < 0 .0 5 4.7±0.16 4.42+0.11 >0.05
p3> 0 .05, p4 
> 0 .0 5
C h o les tero l,
mmol/l 5 .37± 0 .17 5 .15± 0.08  >  0.05 5 ,37+ 0 .16
4.69± 0 .07 <0.001 p 3 > 0.05, p4 
< 0 .0 0 0 1
T rig lycerides,
mmol/l 1.26±0.09 1.19± 0.08 >  0.05 1.37±0.12 0.99± 0,08 <  O .OOl
p 3> 0.05, p4 
> 0 .0 5
B iliru b in : To ta l,
m c M /l
12.48±1.11 12.04±0.81 > 0 .0 5 13.42±1.23 12.56±1.14 >0.05 p 3 > 0 .05, p4 > 0 .0 5
D irect, % o f  to ta l 
In d ire c t, % o f
3.64±0.41 3.32± 0.23 > 0 .0 5 3.9±0.4 3 .64± 0.39 >0.05 p 3 > 0 .05 , p4 > 0 .0 5  
p3 > 0 .05 , p4 
> 0 .0 5
to ta l 8.84+0 .73 8.72±0.61 > 0 .0 5 9.52±0,85 8.8±0.79 >0.05
Tota l p ro te in , g / l 72 .72± 1 .23 73.64± 0.92 >0.05 72 .80± 1 .00 72.68±0.71 >0.05 p3> 0.05, p4> 0.05
T h y m o l tes t 1.72±0.08 1.84±0.12 >0.05 1.9± 0.11 1.58±0.10 < 0 .0 2 p3> 0 .05, p4>  0.05
U rea , m m o l/l 5.46±0.25 5.47±0.35 >0.05 4 .98+ 0 .27 5.11 ±0.28 >0.05 p3> 0 .05, p4>  0.05
C reatin in e , m c M /l 80 .48± 2 .79 83 .12± 3 .24 >0.05 80.32±3.00 83.48±2.93 >0.05 p 3 > 0.05, p4 > 0.05
Residual 
n itro g e n , m m o l/l 25.88± 0.76 25.36± 1.15 >0.05 24.40+ 0 .82 24.41 ±0.78 >0.05
p 3> 0 .05, p4> 
0.05
the efficiency of even the “gold standard” treatment, 
including antihypertensives (ACE inhibitors, beta 
blockers), oral antidiabetic (metformin, sulfonylureas, 
insulin), antiplatelet agents (aspirin, clopidogrel), and 
lipid-lowering agents (statins, fib rates). This study clearly 
demonstrated that pioglitazone can reduce the risk of 
death, myocardial infarction and stroke in patients with 
type 2 diabetes.
In our study, high tolerability of patients receiving 
pioglitazone was revealed; side effects and withdrawal 
of the drug were not detected, which demonstrates the 
effectiveness of this medication in the treatment of asthma 
and coronary heart disease.
Thus, these data demonstrate the anti-inflammatory 
and endothelium protective effects of pioglitazone against 
the background of standard therapy in patients with 
BA concurrent with CHD within 6 months, which may 
enhance the clinical efficacy in the treatment of these 
diseases. The use of pioglitazone in combination with the 
course of conventional therapy is a new, pathogenetically 
justified an effective treatm ent regim en of patients 
with asthma concurrent with CHD, which allows to 
significantly reduce the clinical m anifestations, to 
inhibit the development of inflammation and endothelial 
dysfunction, establish adequate control over the course 
of the disease without causing negative manifestations 
of therapy and therefore can be recommended for use in 
clinical practice.
REFERENCES
1. Tattersall M.C.,Guo M., KorcarzCE, e ta l. Asthma predicts cardiovascular 
disease events: the m u lti-e thn ic  study o f atherosclerosis. A rteriosder 
Thromb Vase Biol. 2015; 35 (6): 1520-1525.
2. Chih-Wei Y.; Te-Chun S.; Chiung-Ray L  e ta l. Asthma is associated w ith  a 
subsequent risk o f peripheral a rtery disease: a longitudinal population- 
based study. Medicine. 2016; 95(3): e2546-e2553.
3. Frostegerd J. Im m unity, atherosclerosis and cardiovascular disease. BMC 
Medicine. 2013,11:117-130.
4. Chetta A., O liv ieri D. Role o f inha led steroids in vascular a irw ay 
remodelling in asthma and C0PD. Int. J. Endocrinol. 2012; 2012:1-6.
5. Patel H J,, Belvisi M.G., Bishop-Bailey D., Yacoub M.H., Mitchell J.A. Activation of 
peroxisome proliferator-activated receptors in human airway smooth muscle cells 
has a superior anti-inflammatory profile to corticosteroids: relevance for chronic 
obstructive pulmonary disease therapy. J. Immunol. 2003; 170(5): 2663-2669.
6. Rinne S.T., Feemster L.C., Collins B.F. et al. Thiazolidinediones and the 
risk o f asthma exacerbation among patients w ith  diabetes: a cohort 
study. A llergy Asthma Clin. Im munol. 2014; 10 (1): 10-34.
7. Anderson J.R., M ortim er K., Pang L. et al. Evaluation o f the  PPAR-y 
agon is t p iog litazone in m ild  asthm a: a doub le -b lind  random ized 
controlled tria l. PLoS ONE. 2016; 11 (8): 1-15.
8. Benayoun L , LetuveS., Druilhe A. etal. Regulation o f peroxisome proliferator- 
activated receptor gamma expression in human asthm atic airways: 
Relationship w ith  proliferation, apoptosis, and airway remodeling. Am. J. 
Respir. Critical Care Medicine. 2001; 164 (8 1): 1487-1494.
9. Kaidashev I.P., Kutsenko N.L. Retseptory, aktiviruyushchiye proliferatsiyu 
peroksisom, kak vozmozhnaya m is h e n 'v  lechenii a llerg icheskikh 
zabolevaniy. Klin imm unol Allergol Infektol 2008; 3(14): 59-63. Russian.
719
Oksana V. Byelan et al.
10. Kaidashev I.R, Bobrova N A , Berkaio L.V., Kutsenko N.L. Novel approach forPPAR-y 
stimulation in thetreatmentofbronchial asthma.2009;l-2(13):32-35.Russian.
11. Nissen S.E., Nicholls S.J., Wolski K. et al. PERISCOPE Investigators. 
Comparison of pioglitazone vs glimepiride on progression of coronary 
atherosclerosis in patients w ith  type 2 diabetes: the PERISCOPE 
randomized controlled trial. JAMA. 2008; 299 (13): 1561-73.
12. Global In itiative for Asthma (GINA). Global strategy for asthma 
management and prevention (updated 2009,2014).
13. Celerm ajer D.S., Sorensen K.E., Gooch V.M. et al. Non-invasive 
detection of endothelial dysfunction in children and adults at risk of 
atherosclerosis. Lancet 1992; 340:1111-1115.
14. Leigh R., MostafaM.M, King E.M .etal. An inhaled dose of budesonide 
induces genes involved in transcription and signaling in the human 
airways: enhancement of anti- and proinflammatcry effector genes. 
Pharmacol. Res. Perspect. 2016; 4(4):e00243-e00261.
15. Byelan O.V., Borzykh O.A., Mamontova T.V., Kaidashev I.P. Clinical 
effectiveness of pioglitazone in the combination treatment of patients 
with asthma concurrent with coronary heart disease. Ter. Arkh. 2015; 
87 (9): 44-51. Russian.
16. Ei-sakkarM.G., Barghash A. The efficacy of simvastatin and pioglitazone in 
a murine model of chronic asthma. Bull. Alex. Fac. Med. 2006; 42 (2): 51 -59.
17. Narala V.R., Ranga R., Smith M.R. et al. Pioglitazone is as effective as 
dexametasone in cockroach allergen-induced murine model of asthma. 
Respir. Res. 2007; 8:90-95.
18. Belan O.V., Kaidashev I.P., Borzykh O.A. The features of risk factors, 
systemic inflammation, and endothelial dysfunction in patients with 
asthma concurrent with coronary heart disease. Ter. Arkh. 2014; 86 (3): 
34-9. Russian.
19. Kim S.R., Lee K.S., Park H.S. et al. Involvement of IL-10 in peroxisome 
proliferator-activated receptor y-mediated anti-inflammatory response 
in asthma. Mol. Pharmacol. 2005; 68(6): 1568-1575.
20. Honda K., Marquillies P., Capron M. et al. Peroxisome proliferator- 
activated receptor y is expressed in airways and inhibits features of 
airway remodeling in a mouse asthma model. J. Allergy Clin. Immunol. ; 
2004;113:882-888.
21. Hanefeld M., Marx N., Pfutzner A. et al. Anti-inflammatory effects of 
pioglitazone and /  or simvastatin in high cardiovascular risk patients ' 
with elevated high sensitivity c-reactive protein The PIOSTAT Study. J. 
Am. Coll. Cardiol. 2007; 49:290-297.
22. Mazzone T., Meyer P.M., Feinstein S.B. et al. Effect of pioglitazone 
compared with glimepiride on carotid intimamedia thickness in type 
2 diabetes: a randomized trial. JAMA. 2006; 296 (21): 2572-2581.
A D D R E S S  F O R  C O R R E S P O N D E N C E  
Oksana Byelan
te l.+380664503394,
e-mail: Litwinenko.oxana@yandex.ru
Received: 22.05.2017 
Accepted: 28.08.2017
720
